Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-Arterial Neuroprotective Agents and Cold Saline for Acute Ischemic Stroke
NCT05032781Phase 1Withdrawn
- Sponsor
- Northwell Health
- Start
- Jun 2021
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of minocycline and magnesium sulfate in ischemic stroke, sponsored by Northwell Health. Primary endpoints: Intracranial Hemorrhage at 24 hours and Serious Adverse Event at 72 hours. Planned start Jun 2021; status: withdrawn.
02
Drugs
minocyclinemagnesium sulfate
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05032781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05032781.